Long-term exon skipping studies with 2'-o-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models

Molecular Therapy Nucleic Acids

Volumn 1, Issue 9, 2012, Pages e44-

  Tanganyika De Winter, Christa L ^a   Heemskerk, Hans ^a   Karnaoukh, Tatyana G ^b   Putten, Maaike Van ^a   De Kimpe, Sjef J ^b   Deutekom, Judith Van ^b   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa BV   (Netherlands)

Author keywords

Antisense oligonucleotides; Duchenne muscular dystrophy; Dystrophin; Exon skipping; Mouse models; Therapy

Indexed keywords

EID: 84868340660     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.38     Document Type: Article

References (38)

1. Aartsma-Rus, A and van Ommen, GJ (2010). Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 18: 146-153.
2. van Ommen, GJ, van Deutekom, J and Aartsma-Rus, A (2008). The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10: 140-149. (Pubitemid 351498876)
3. Monaco, AP, Bertelson, CJ, Liechti-Gallati, S, Moser, H and Kunkel, LM (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95.
4. Emery, AE (2002). The muscular dystrophies. Lancet 359: 687-695. (Pubitemid 34203773)
5. Aartsma-Rus, A, Fokkema, I, Verschuuren, J, Ginjaar, I, van Deutekom, J, van Ommen, GJ et al. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30: 293-299.
6. Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8: 918-928.
7. van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer- Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
8. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
9. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
10. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177. (Pubitemid 43214742)
11. Mann, CJ, Honeyman, K, McClorey, G, Fletcher, S and Wilton, SD (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4: 644-654. (Pubitemid 40277188)
12. Yin, H, Lu, Q and Wood, M (2008). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16: 38-45.
13. Yokota, T, Lu, QL, Partridge, T, Kobayashi, M, Nakamura, A, Takeda, S et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65: 667-676.
14. Heemskerk, H, de Winter, C, van Kuik, P, Heuvelmans, N, Sabatelli, P, Rimessi, P et al. (2010). Preclinical PK and PD studies on 2'-O-methyl- phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18: 1210-1217.
15. Malerba, A, Thorogood, FC, Dickson, G and Graham, IR (2009). Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20: 955-965.
16. Malerba, A, Sharp, PS, Graham, IR, Arechavala-Gomeza, V, Foster, K, Muntoni, F et al. (2011). Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19: 345-354.
17. Chamberlain, JS, Metzger, J, Reyes, M, Townsend, D and Faulkner, JA (2007). Dystrophin- deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 21: 2195-2204. (Pubitemid 47026454)
18. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cell- penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918. (Pubitemid 352762853)
19. McClorey, G, Moulton, HM, Iversen, PL, Fletcher, S and Wilton, SD (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13: 1373-1381. (Pubitemid 44420632)
20. Walmsley, GL, Arechavala-Gomeza, V, Fernandez-Fuente, M, Burke, MM, Nagel, N, Holder, A et al. (2010). A duchenne muscular dystrophy gene hot spot mutation in dystrophindeficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS ONE 5: e8647.
21. Deconinck, AE, Rafael, JA, Skinner, JA, Brown, SC, Potter, AC, Metzinger, L et al. (1997). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727. (Pubitemid 27357963)
22. Goyenvalle, A, Babbs, A, Powell, D, Kole, R, Fletcher, S, Wilton, SD et al. (2010). Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18: 198-205.
23. Zhou, L, Rafael-Fortney, JA, Huang, P, Zhao, XS, Cheng, G, Zhou, X et al. (2008). Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci 264: 106-111. (Pubitemid 350186318)
24. Huang, P, Cheng, G, Lu, H, Aronica, M, Ransohoff, RM and Zhou, L (2011). Impaired respiratory function in mdx and mdx/utrn(+/-) mice. Muscle Nerve 43: 263-267.
25. van Putten, M, Kumar, D, Hulsker, M, Hoogaars, WM, Plomp, JJ, van Opstal, A et al. (2012). Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord 22: 406-417.
26. Willmann, R, Luca, AD, Benatar, M, Grounds, M, Dubach, J, Raymackers, JM et al.; TREAT-NMD Neuromuscular Network. (2012). Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 22: 43-49.
27. Heemskerk, H, de Winter, CL, van Ommen, GJ, van Deutekom, JC and Aartsma-Rus, A (2009). Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci 1175: 71-79.
28. Heemskerk, HA, de Winter, CL, de Kimpe, SJ, van Kuik-Romeijn, P, Heuvelmans, N, Platenburg, GJ et al. (2009). In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
29. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203. (Pubitemid 40094452)
30. Oberbauer, R, Schreiner, GF and Meyer, TW (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48: 1226-1232.
31. Zhou, L, Rafael-Fortney, JA, Huang, P, Zhao, XS, Cheng, G, Zhou, X et al. (2008) Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci 264: 106-111. (Pubitemid 350186318)
32. van Putten, M, Hulsker, M, Nadarajah, VD, van Heiningen, SH, van Huizen, E, van Iterson, M et al. (2012). The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 7: e31937.
33. Malerba, A, Boldrin, L and Dickson, G (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther 21: 293-298.
34. Wu, B, Lu, P, Benrashid, E, Malik, S, Ashar, J, Doran, TJ et al. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17: 132-140.
35. Cacchiarelli, D, Martone, J, Girardi, E, Cesana, M, Incitti, T, Morlando, M et al. (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 12: 341-351.
36. Verhaart, IE, Heemskerk, H, Karnaoukh, TG, Kolfschoten, IG, Vroon, A, van Ommen, GJ et al. (2012). Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. Hum Gene Ther 23: 262-273.
37. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25. (Pubitemid 34492838)
38. Spitali, P, Heemskerk, H, Vossen, RH, Ferlini, A, den Dunnen, JT, 't Hoen, PA et al. (2010). Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest 90: 1396-1402.